CoChat

Human Placenta-Derived Adherent Cells Prevent Bone loss, Stimulate Bone formation, and Suppress Growth of Multiple Myeloma in Bone

Open access
Li, Xin, Ling, Wen, Pennisi, Angela, Wang, Yuping, Khan, Sharmin, Heidaran, Mohammad, Pal, Ajai, Zhang, Xiaokui, He, Shuyang, Zeitlin, Andy, Abbot, Stewart, Faleck, Herbert, Hariri, Robert, Shaughnessy, John D., van Rhee, Frits, Nair, Bijay, Barlogie, Bart, Epstein, Joshua, Yaccoby, Shmuel · 2011 · Stem Cells
Cited by 83

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Human placenta has emerged as a valuable source of transplantable cells of mesenchymal and hematopoietic origin for multiple cytotherapeutic purposes, including enhanced engraftment of hematopoietic stem cells, modulation of inflammation, bone repair, and cancer. Placenta-derived adherent cells (PDACs) are mesenchymal-like stem cells isolated from postpartum human placenta. Multiple myeloma is closely associated with induction of bone disease and large lytic lesions, which are often not repaired and are usually the sites of relapses. We evaluated the antimyeloma therapeutic potential, in vivo survival, and trafficking of PDACs in the severe combined immunodeficiency (SCID)–rab model of medullary myeloma-associated bone loss. Intrabone injection of PDACs into nonmyelomatous and myelomatous implanted bone in SCID-rab mice promoted bone formation by stimulating endogenous osteoblastogenesis, and most PDACs disappeared from bone within 4 weeks. PDACs inhibitory effects on myeloma bone disease and tumor growth were dose-dependent and comparable with those of fetal human mesenchymal stem cells (MSCs). Intrabone, but not subcutaneous, engraftment of PDACs inhibited bone disease and tumor growth in SCID-rab mice. Intratumor injection of PDACs had no effect on subcutaneous growth of myeloma cells. A small number of intravenously injected PDACs trafficked into myelomatous bone. Myeloma cell growth rate in vitro was lower in coculture with PDACs than with MSCs from human fetal bone or myeloma patients. PDACs also promoted apoptosis in osteoclast precursors and inhibited their differentiation. This study suggests that altering the bone marrow microenvironment with PDAC cytotherapy attenuates growth of myeloma and that PDAC cytotherapy is a promising therapeutic approach for myeloma osteolysis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/stem.572

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 40

  1. Walker, 2007, Magnetic resonance imaging in multiple myeloma: Diagnostic and clinical implications, J Clin Oncol, 25, 1121, 10.1200/JCO.2006.08.5803 · DOI · Paper page
  2. Bartel, 2009, F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma, Blood, 114, 2068, 10.1182/blood-2009-03-213280 · DOI · Paper page
  3. Berenson, 1996, Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group, N Engl J Med, 334, 488, 10.1056/NEJM199602223340802 · DOI · Paper page
  4. Zangari, 2005, Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma, Br J Haematol, 131, 71, 10.1111/j.1365-2141.2005.05733.x · DOI · Paper page
  5. Pennisi, 2009, The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo, Am J Hematol, 84, 6, 10.1002/ajh.21310 · DOI
  6. Breitkreutz, 2008, Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma, Leukemia, 22, 1925, 10.1038/leu.2008.174 · DOI · Paper page
  7. Stewart, 2006, Role of osteoblast suppression in multiple myeloma, J Cell Biochem, 98, 1, 10.1002/jcb.20774 · DOI
  8. Yaccoby, 2007, Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo, Blood, 109, 2106, 10.1182/blood-2006-09-047712 · DOI · Paper page
  9. Tian, 2003, The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma, N Engl J Med, 349, 2483, 10.1056/NEJMoa030847 · DOI · Paper page
  10. Oshima, 2005, Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2, Blood, 106, 3160, 10.1182/blood-2004-12-4940 · DOI · Paper page
  11. Ehrlich, 2005, IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma, Blood, 106, 1407, 10.1182/blood-2005-03-1080 · DOI · Paper page
  12. Giuliani, 2005, Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation, Blood, 106, 2472, 10.1182/blood-2004-12-4986 · DOI · Paper page
  13. Bataille, 1991, Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma, J Clin Invest, 88, 62, 10.1172/JCI115305 · DOI · Paper page
  14. Wallace, 2001, Abnormalities of bone marrow mesenchymal cells in multiple myeloma patients, Cancer, 91, 1219, 10.1002/1097-0142(20010401)91:7<1219::AID-CNCR1122>3.0.CO;2-1 · DOI · Paper page
  15. Mitsiades, 2007, The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies, Hematol Oncol Clin North Am, 21, 1007, 10.1016/j.hoc.2007.08.007 · DOI
  16. Prockop, 2007, Clinical trials with adult stem/progenitor cells for tissue repair: Let's not overlook some essential precautions, Blood, 109, 3147, 10.1182/blood-2006-03-013433 · DOI · Paper page
  17. Pittenger, 1999, Multilineage potential of adult human mesenchymal stem cells, Science, 284, 143, 10.1126/science.284.5411.143 · DOI · Paper page
  18. Uccelli, 2008, Mesenchymal stem cells in health and disease, Nat Rev Immunol, 8, 726, 10.1038/nri2395 · DOI · Paper page
  19. Prockop, 2007, “Stemness” does not explain the repair of many tissues by mesenchymal stem/multipotent stromal cells (MSCs), Clin Pharmacol Ther, 82, 241, 10.1038/sj.clpt.6100313 · DOI · Paper page
  20. Horwitz, 1999, Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta, Nat Med, 5, 309, 10.1038/6529 · DOI · Paper page
  21. Parolini, 2008, Concise review: Isolation and characterization of cells from human term placenta: Outcome of the first international Workshop on Placenta Derived Stem Cells, Stem Cells, 26, 300, 10.1634/stemcells.2007-0594 · DOI · Paper page
  22. Prather, 2008, Placental-derived and expanded mesenchymal stromal cells (PLX-I) to enhance the engraftment of hematopoietic stem cells derived from umbilical cord blood, Expert Opin Biol Ther, 8, 1241, 10.1517/14712598.8.8.1241 · DOI
  23. Yata, 2004, The SCID-rab model: A novel in vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells, Leukemia, 18, 1891, 10.1038/sj.leu.2403513 · DOI
  24. Yen, 2005, Isolation of multipotent cells from human term placenta, Stem Cells, 23, 3, 10.1634/stemcells.2004-0098 · DOI · Paper page
  25. Barlow, 2008, Comparison of human placenta- and bone marrow-derived multipotent mesenchymal stem cells, Stem Cells Dev, 17, 1095, 10.1089/scd.2007.0154 · DOI · Paper page
  26. Fukuchi, 2004, Human placenta-derived cells have mesenchymal stem/progenitor cell potential, Stem Cells, 22, 649, 10.1634/stemcells.22-5-649 · DOI · Paper page
  27. Shaughnessy, 2007, A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1, Blood, 109, 2276, 10.1182/blood-2006-07-038430 · DOI · Paper page
  28. Zhan, 2006, The molecular classification of multiple myeloma, Blood, 108, 2020, 10.1182/blood-2005-11-013458 · DOI · Paper page
  29. Li, 2007, Establishment and exploitation of hyperdiploid and non-hyperdiploid human myeloma cell lines, Br J Haematol, 138, 802, 10.1111/j.1365-2141.2007.06742.x · DOI
  30. Yaccoby, 2006, Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model, Haematologica, 91, 192
  31. Yaccoby, 1998, Primary myeloma cells growing in SCID-hu mice: A model for studying the biology and treatment of myeloma and its manifestations, Blood, 92, 2908, 10.1182/blood.V92.8.2908 · DOI · Paper page
  32. Yaccoby, 1999, The proliferative potential of myeloma plasma cells manifest in the SCID-hu host, Blood, 94, 3576, 10.1182/blood.V94.10.3576.422k01_3576_3582 · DOI · Paper page
  33. Yaccoby, 2004, Cancer and the microenvironment: Myeloma-osteoclast interactions as a model, Cancer Res, 64, 2016, 10.1158/0008-5472.CAN-03-1131 · DOI · Paper page
  34. Qiang, 2008, Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth, Blood, 112, 374, 10.1182/blood-2007-10-120253 · DOI · Paper page
  35. Prockop, 2009, Repair of tissues by adult stem/progenitor cells (MSCs): Controversies, myths, and changing paradigms, Mol Ther, 17, 939, 10.1038/mt.2009.62 · DOI · Paper page
  36. Caligaris-Cappio, 1991, Role of bone marrow stromal cells in the growth of human multiple myeloma, Blood, 77, 2688, 10.1182/blood.V77.12.2688.2688 · DOI · Paper page
  37. Pennisi, 2009, The ephrinB2/EphB4 axis is dysregulated in osteoprogenitors from myeloma patients and its activation affects myeloma bone disease and tumor growth, Blood, 114, 1803, 10.1182/blood-2009-01-201954 · DOI · Paper page
  38. Edwards, 2008, Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo, Blood, 111, 2833, 10.1182/blood-2007-03-077685 · DOI · Paper page
  39. Yaccoby, 2010, Advances in the understanding of myeloma bone disease and tumour growth, Br J Haematol, 149, 311, 10.1111/j.1365-2141.2010.08141.x · DOI · Paper page
  40. Kidd, 2009, Direct evidence of mesenchymal stem cell tropism for tumor and wounding microenvironments using in vivo bioluminescent imaging, Stem Cells, 27, 2614, 10.1002/stem.187 · DOI · Paper page

Cited by

See all 83

Metadata

Authors
Li, X., Ling, W., Pennisi, A., Wang, Y., Khan, S., Heidaran, M., Pal, A., Zhang, X., He, S., Zeitlin, A., Abbot, S., Faleck, H., Hariri, R., Shaughnessy, J. D., van Rhee, F., Nair, B., Barlogie, B., Epstein, J., & Yaccoby, S.
Venue
Stem Cells
Published
2011-02-01
Volume
29
Issue
2
Pages
263-273
ISSN
  • 1066-5099 (ISSN-L)
  • 1549-4918
OpenAlex
W2074379284
Cited by
83
References
7
FWCI
3.37
Type
journal article
Language
en
Open access
bronze
Funders
  • Celgene Cellular Therapeutics (CA-093897)
  • National Cancer Institute (CA55819, CA113992)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.